Esophageal Squamous Cell Carcinoma Market Share

Global Esophageal Squamous Cell Carcinoma Market Overview

The Esophageal Squamous Cell Carcinoma Market size was valued at USD 0.77 billion in 2022 and is projected to grow from USD 1.25 Billion in 2023 to USD 1.45 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 8.16% during the forecast period (2023 - 2032). The growing increasing prevalence of Achalasia, increased research activities & product approvals, and rising public awareness are driving market growth.

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

In May 2024, Glenmark Specialty SA, a subsidiary of Glenmark Pharma, revealed a contract for exclusive marketing and distribution with BeiGene, a worldwide oncology firm. According to a statement from the business, Glenmark will be responsible for the registration and commercialization of BeiGene's oncology drugs, Tislelizumab and Zanubrutinib, in India. Tislelizumab is a newly developed monoclonal antibody that targets the PD-1 protein. It has been approved by the NMPA, EMA, and FDA for treating advanced or metastatic esophageal squamous cell carcinoma. Additionally, it is being extensively studied for its potential in treating different types of cancers. 

In March 2024, the FDA granted approval for tislelizumab-jsgr (Tevimbra) as a standalone treatment for patients with unresectable or metastatic esophageal squamous cell carcinoma (ESCC) who have previously had systemic chemotherapy, excluding the use of a PD-L1 inhibitor. This information was provided in a press statement by BeiGene, the company responsible for developing the drug. Tislelizumab is expected to be commercially accessible in the United States during the latter part of 2024, as stated by the developers. The approval was granted after evaluating the outcomes of the phase 3 RATIONALE 302 study (NCT03430843), which compared the effectiveness of tislelizumab as a standalone treatment versus chemotherapy in the second-line treatment for this group of patients. 

Esophageal Squamous Cell Carcinoma Market Trends

• The increasing prevalence of achalasia to boost the market growth.

The increasing prevalence of achalasia aid market growth because achalasia patients have a higher risk of Esophageal Squamous Cell Carcinoma than the general population. The journal Annals of Oesophagus reports that 9 to 10 people per 100,000 people experience achalasia each year.

Furthermore, achalasia can cause food retention, which can lead to bacterial overgrowth, irritation, and chronic inflammation, a pathophysiological process that has been proposed to lead to squamous cell carcinoma. Moreover, two recent meta-analyses found that the incidence rate of squamous cell carcinoma in patients with achalasia ranges from 1.36/1,000 patients-years to 3.12/1,000 patients-years, with risks of 1.5% and 2.8%, respectively.

Moreover, according to the International Agency for Research on Cancer, these rates are 15 and 34 times higher, respectively, than the risk of Esophageal Squamous Cell Carcinoma in the general population. Therefore, increasing prevalence of achalasia will directly affect the market growth of global Esophageal Squamous Cell Carcinoma positively.

Esophageal Squamous Cell Carcinoma Market Segment Insights

Esophageal Squamous Cell Carcinoma Diagnosis and Treatment Insights

The Market segments of Esophageal Squamous Cell Carcinoma, based on diagnosis and treatment, whereas, diagnosis is further segmented into Endoscopy, CT scan, Esophagram, Positron Emission Tomography (PET) and others. Likewise, treatment is further segregated into Surgery, Chemotherapy, Radiotherapy, Immunotherapy, And Others.

Treatment Segment dominated the market in 2022, while the diagnosis segment is projected to be the fastest-growing during the forecast period, 2023–2030 in the Esophageal Squamous Cell Carcinoma Market revenue. This is due to the increasing prevalence of cancer, introduction of new highly effective medications with lower secondary effects and rising demand for chemotherapy for the market's expansion.

June 2022: Eli Lilly and Company and Innovent Biologics, Inc. (China), a biopharmaceutical company, announced approval for TYVYT (sintilimab injection) for first line treatment for Esophageal Squamous Cell Carcinoma by the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA).

Esophageal Squamous Cell Carcinoma End User Insights

The Esophageal Squamous Cell Carcinoma Market segmentation is based on end user which includes hospitals, specialty centers and others.

The hospital segment dominated the market in 2022. This is attributed to the rising prevalence of cancer further require drug discovery and development which fuels the market growth. While the specialty centers segment is projected to be the fastest–growing segment during the forecast period, 2022–2032.

Increased research & development also fuels the market growth of Esophageal Squamous Cell Carcinoma. For instance, according to the research done by Western Reserve University, U.S. in February 2019 found that the most prevalent esophageal cancer in the US, esophageal adenocarcinoma, could be reduced by blocking two molecular pathways that send signals inside cancer cells (EAC). This demonstrated the effectiveness of a novel therapeutic strategy for the treatment of esophageal cancer known as JNK/TGF-beta-targeted therapy.

Figure 2: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY MOLECULE TYPE, 2022 & 2032 (USD Billion)

Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review

Esophageal Squamous Cell Carcinoma Regional Insights

By Region, the study segments the market into North America, Europe, Asia-Pacific, and the Rest of the World. The North America Esophageal Squamous Cell Carcinoma market accounted for the largest market share in 2022. This is due to the rising prevalence of esophageal cancer which is raising the demand for the Esophageal Squamous Cell Carcinoma treatment market. Moreover, the increasing investment by major key players in better treatment alternatives is also expected to foster North America’s market growth.

Further, the major countries studied are the U.S., Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 3: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET SHARE BY REGION 2022 & 2032

Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review

Europe Esophageal Squamous Cell Carcinoma market accounts for the second-largest market share due to the rising inclination towards smoke, tobacco, and drink is driving up demand for an advanced treatment option for Esophageal Squamous Cell Carcinoma. Moreover, rising healthcare expenditure is also expected to support the growth of the market. further, the Germany market of Esophageal Squamous Cell Carcinoma was attributed to hold the largest market share, and the Rest of Europe expected to fastest-grow during the forecast period.

The Asia-Pacific Esophageal Squamous Cell Carcinoma market is expected to grow at a significant share from 2023 to 2032. This is due to factors such as the rising incidence of Esophageal Squamous Cell Carcinoma, and the high population of tobacco smoking and alcohol drinking in this region is further expected to boost the market growth. Furthermore, the Increasing physical inactivity and poor lifestyle are also expected to boost the growth of the regional market. Moreover, China market of Esophageal Squamous Cell Carcinoma is expected to hold the largest market share, and Rest of Asia-Pacific market is expected fastest-growing region.

The Rest of the World is segmented into the Middle East, Africa, and Latin America. The market in the above-mentioned regions is likely to witness growth due to strong epidemiological factors, and improving healthcare facilities, increasing awareness about healthy lifestyles. Moreover, improving medical infrastructure in developing and underdeveloped countries, and growing inclination towards advanced treatment solution further drive the market growth of the Esophageal Squamous Cell Carcinoma in the regions clustered as Rest of the World.

Esophageal Squamous Cell Carcinoma Key Market Players & Competitive Insights

The Esophageal Squamous Cell Carcinoma Market is characterized by the presence of many global, regional, and local vendors catering to the demand created by research scientists and pharmaceutical and biotechnology companies operating in the industry. The market comprises tier-1, tier-2, and local players. The tier-1 and tier-2 players have reach across the globe with diverse product portfolios. Companies such as include Chia Tai Tianqing Pharmaceutical Group Co. Ltd. (China) and Seagen Inc. (US) among others, dominate the Market of Esophageal Squamous Cell Carcinoma due to product differentiation, financial stability, strategic developments, and diversified regional presence. The players are focused on investing in research and development. Furthermore, they adopt strategic growth initiatives, such as expansion, product launches, joint ventures, and partnerships, to strengthen their market position and capture a large customer base.

One of the primary business strategies adopted by manufacturers in the global Esophageal Squamous Cell Carcinoma industry to benefit clients and expand the market of Esophageal Squamous Cell Carcinoma sector is to manufacture locally to reduce operating costs.

• Hoffmann-La Roche Ltd (Roche) is one of the leading companies in the field of diagnostics and pharmaceuticals. It develops and markets products for the diagnosis & treatment of anemia, cancer, anticoagulation therapy, cardiovascular diseases, diabetes, central nervous system, chlamydia, dermatology, gonorrhea, gout, hepatitis B and C, hemostasis disorders, HIV/AIDS, HPV, infectious diseases, and autoimmune diseases. The company supplies in-vitro diagnostics and drugs for cancer and transplantation. Moreover, it specializes in the field of molecular diagnostics and medicines for oncology, virology, inflammation, metabolism, central nervous system (CNS), clinical chemistry, immunology, urinalysis, blood screening, genetics, infectious diseases, and microbiology. In addition, the company has offices and subsidiaries throughout the Americas, Europe, the Middle East, Africa, and Asia-Pacific.

Also, AstraZeneca is a leading biopharmaceutical company. It focuses on developing and commercializing prescribed medicines. It has three main therapy areas, namely, cardiovascular, and metabolic disease (CVMD), oncology, and respiratory. It is also active in areas such as neuroscience autoimmunity and infection. It has more than 164 projects in its pipeline, nine new molecular entities in its late-stage pipeline, and one new molecular entity approval in the last quarter of 2019. Its product portfolio includes medications in the field of oncology, cardiovascular, renal & metabolism, and respiratory diseases, among others. Geographically the company operates in more than 100 countries by offering its healthcare products to millions of people across the globe.

Key Companies in the market of Esophageal Squamous Cell Carcinoma include

• Hoffmann-La Roche Ltd


• AstraZeneca


• Chia Tai Tianqing Pharmaceutical Group Co. Ltd.


• Seagen Inc.


• Eli Lilly and Company


• Glaxosmithkline Plc


• Novartis AG


• Beijing Shenzhou Cell Biotechnology Group Co., Ltd.


• Jacobio Pharmaceuticals Group Co., Ltd

Esophageal Squamous Cell Carcinoma Industry Developments

September 2021: The FDA has approved Seagen Inc’s TIVDAK (Tisotumab vedotin). It is used to treat cervical cancer that is recurrent or metastatic and Esophageal Squamous Cell Carcinoma cancer. It is also used in women whose cancer got worse during or after treatment with chemotherapy.

September 2022: The US FDA has approved AstraZeneca's Imfinzi plus in the US for patients with advanced biliary tract cancer, HCC, BTC, esophageal and gastric cancer.

Esophageal Squamous Cell Carcinoma Market Segmentation

Esophageal Squamous Cell Carcinoma Diagnosis and Treatment Outlook

• Diagnosis
  
  
  
  • Endoscopy
  
  
  • CT Scan
  
  
  • Esophagram
  
  
  • Positron Emission Tomography (PET)
  
  
  • Others
  
  
  
  


• Treatment
  
  
  
  • Surgery
  
  
  • Chemotherapy
  
  
  • Radiotherapy
  
  
  • Immunotherapy
  
  
  • Others
  
  
  
  

Esophageal Squamous Cell Carcinoma End User Outlook

• Hospitals


• Specialty Centres


• Others

Esophageal Squamous Cell Carcinoma Regional Outlook

• North America
  
  
  
  • US
  
  
  • Canada
  
  
  
  


• Europe
  
  
  
  • Germany
  
  
  • France
  
  
  • UK
  
  
  • Italy
  
  
  • Spain
  
  
  • Rest of Europe
  
  
  
  


• Asia-Pacific
  
  
  
  • China
  
  
  • Japan
  
  
  • India
  
  
  • Australia
  
  
  • South Korea
  
  
  • Rest of Asia-Pacific
  
  
  
  


• Rest of the World
  
  
  
  • Middle East
  
  
  • Africa
  
  
  • Latin America